An Open-label Phase 1 Safety Study of SANGUINATE Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion

Trial Profile

An Open-label Phase 1 Safety Study of SANGUINATE Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs PEG-haemoglobin carbon monoxide (Primary)
  • Indications Anaemia
  • Focus Adverse reactions
  • Sponsors Prolong Pharmaceuticals
  • Most Recent Events

    • 17 May 2017 Status changed from recruiting to completed.
    • 22 Mar 2017 Planned number of patients changed from 10 to 100.
    • 22 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top